Watch ASCO president Dr. Clifford Hudis discuss 2014 Annual meeting theme: Science and Society
There are just a few days to go before the ASCO general
meeting gets under way in Chicago, with this year’s theme being “Science and
Society”. 2014 represents a golden anniversary
for ASCO, as it is now the 50th year of its continued support and
advocacy of the continued development of oncological science for society.
A traditional gift for a 50th anniversary is
gold, and ASCO has once again delivered a wealth of important information, over
5000 abstracts released this year, each selected for its relevance to
continuing the advance in cancer research and improvements in patient care.
The Branding Science Group has been around for a quarter of
that time and has continuously supported the creation and development of
Oncology brands. For this reason, we
will be paying particular attention to discussions around;
-
New developments amongst targeted therapies - In
particular those relating to Breast Cancer, Chronic Lymphocytic Leukaemia and
Non-Small Cell Lung Cancer. These
indications are all facing significant change with multiple new market entrants
bringing increased hope for patients, but potential headaches for prescribing
physicians and payers.
-
Progress in immunotherapy - conceptually one of
the most exciting areas of Oncology (working with your own immune system to
fight malignancies) as well as one with real momentum and a highly anticipated
future development pipeline.
-
Improving patient care and quality of life –
remembering that ASCO is not all about the Science, it’s about improving
patient lives and end of life care. Here
there are a number of interesting studies evaluating how lower intensity
treatment regimens or a greater focus on palliation can improve the survival
vs. QoL balance for patients and their carers.
We hope that you also enjoy ASCO 2014 and would be delighted
to hear your thoughts on this golden year.
What are you most looking forward to?
What do you think will be the most interesting discussion this year? Which new data will especially change patient
outcomes for the better?
No comments:
Post a Comment